The CDC6 antibody is a crucial tool for studying the cell division cycle 6 (CDC6) protein, a key regulator of DNA replication and cell cycle progression. CDC6 is essential for the assembly of the pre-replication complex (pre-RC) during the G1 phase, ensuring precise initiation of DNA replication. Structurally, it contains an AAA+ ATPase domain and collaborates with the origin recognition complex (ORC) and Cdt1 to load mini-chromosome maintenance (MCM) helicases onto replication origins. Dysregulation of CDC6 is linked to genomic instability, uncontrolled proliferation, and tumorigenesis, with overexpression observed in cancers like breast, lung, and colorectal.
CDC6 antibodies are widely used in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to detect protein expression, localization, and dynamics across cell cycle stages. They help investigate CDC6's roles in replication licensing, checkpoint control, and its interplay with tumor suppressors (e.g., p53) or oncogenic pathways. Monoclonal antibodies (e.g., clone DCS-180) offer high specificity, while polyclonal versions may detect conserved epitopes across species. Validation often includes knockout/knockdown controls to confirm target specificity.
Research using CDC6 antibodies has highlighted its potential as a diagnostic marker for cancer prognosis and therapeutic targeting, particularly in disrupting replication in rapidly dividing cells. These studies underscore its importance in both basic cell biology and translational oncology.